Timing clarification: STERIS will release fiscal 2027 first-quarter results after the U.S. market close on Wednesday, August 5, 2026, followed by its earnings call at 9:00 a.m. ET on Thursday, August 6, 2026. This is therefore an FY27 Q1 report—not a “2027Q1 Earnings Call” occurring on August 5.
STERIS enters FY27 Q1 with a constructive fundamental setup but a high bar for execution. Management’s full-year framework calls for 6–7% constant-currency organic revenue growth, 7–8% reported revenue growth, and $11.10–$11.30 of adjusted EPS, implying 9–11% EPS growth. The central debate is not whether STERIS can grow—its Healthcare recurring-revenue model, procedure-volume exposure, and sterilization franchise remain attractive—but whether growth and margins can support the annual outlook amid a softer near-term setup for Applied Sterilization Technologies (AST).
The most important message for investors will be whether management still sees FY27 as a year of acceleration after a slower first half, particularly in AST. A clean Q1 result that maintains guidance, demonstrates resilient Healthcare demand, and shows AST softness is limited to expected inventory/comparison effects would support the longer-term earnings algorithm. Conversely, a weak AST volume result coupled with weaker-than-expected margin conversion or a guide reduction would likely matter more than a modest EPS miss or beat.
| Metric | FY27 management outlook |
|---|---|
| Reported revenue growth | 7–8% |
| Constant-currency organic revenue growth | 6–7% |
| Healthcare organic growth | 6–7% |
| AST organic growth | 7–8% |
| Life Sciences organic growth | 6–7% |
| Adjusted EPS | $11.10–$11.30 |
| EBIT-margin expansion | Approximately 50 bps at the high end of guidance |
| Free cash flow | Approximately $850 million |
| Capital expenditures | Approximately $375 million |
Two components of reported growth are already identifiable: modest favorable currency and approximately $45 million of full-year contribution from two Healthcare tuck-in acquisitions—MEDglas and a GI-products business.
AST is the highest-priority swing factor. In FY26 Q4, AST delivered only 2% constant-currency organic growth, after weather disruption and softer customer volumes. Management characterized the broader issue as med-tech customers managing inventory carefully, while arguing underlying procedure demand and end-market demand remain healthy.
Importantly, management explicitly guided investors to expect a slower first half for AST because of difficult comparisons, followed by better growth in FY27 Q3 and easier comparisons in Q4. That makes a merely modest AST growth rate in Q1 less concerning by itself. The issue is whether results validate the premise that the softness is temporary inventory normalization rather than a deterioration in sterilization demand.
What to look for in AST: - Organic growth and the split between price and volume. - Management’s view of med-tech customer inventory behavior. - Evidence that weather-disrupted volumes from FY26 Q4 are recovering. - Whether the expected second-half reacceleration remains intact. - Service revenue growth, which is a better read-through on underlying processing demand than the small, inherently lumpy capital-equipment line.
A result that is weak but consistent with management’s first-half caution should be manageable. A result that prompts lower AST guidance or introduces concern about procedure-related volumes would be a more material negative.
Healthcare is STERIS’s largest business and the principal determinant of whether the company can sustain its mid-to-high-single-digit organic-growth profile. In FY26 Q4, Healthcare grew 6% organically in constant currency, supported by service growth of 9%, consumables growth of 7%, and capital-equipment growth of 6%.
The setup remains favorable: U.S. procedure volumes were described as growing at a mid-single-digit pace, and STERIS’s service, consumables, workflow, and sterile-processing offerings are positioned around hospital customers’ need to support more procedures while improving efficiency and compliance.
Key items for the report:
Life Sciences returned to growth in FY26, with 7% constant-currency organic revenue growth for the full year. Capital equipment recovered as customers resumed investment, while consumables—typically the segment’s highest-quality and higher-margin revenue stream—grew 8% in FY26.
Management has cited constructive activity around larger pharmaceutical customers and U.S. reshoring, particularly new facilities in the East Coast and Carolinas. However, it has also acknowledged that smaller customer investment remains less healthy.
For Q1, investors should focus on:
STERIS delivered FY26 adjusted EPS growth of 10% despite approximately $46 million of incremental tariff costs, or roughly 80 bps of margin pressure. For FY27, the company expects total tariff expense of approximately $60–65 million, effectively flat year over year, and has said recent tariff changes were favorable enough to offset the expected increase in volume.
That setup creates a plausible path to margin expansion. At the high end of FY27 guidance, STERIS expects approximately 50 bps of EBIT-margin expansion, helped by productivity, mix, and a roughly $20 million incentive-compensation tailwind from normalizing performance compensation.
However, the margin outcome is not automatic. Investors should listen for:
A reaffirmed outlook with credible margin commentary would be a positive signal; a guide that depends on an unusually back-end-loaded margin recovery would be less reassuring.
The year-ago quarter sets a meaningful comparison:
| FY26 Q1 reported result | Result |
|---|---|
| Revenue | $1.391 billion |
| Constant-currency organic growth | 8% |
| Adjusted EPS | $2.34 |
| Healthcare organic growth | 8% |
| AST organic growth | 10% |
| Life Sciences organic growth | 4% |
| Free cash flow | $326.5 million |
The Q1 FY26 AST comparison is particularly demanding, which supports management’s caution about first-half AST growth. Accordingly, the market is likely to judge Q1 more on the integrity of the full-year trajectory than on whether every segment posts the annualized target immediately.
STERIS ended FY26 with approximately $1.9 billion of debt and gross debt-to-EBITDA near 1.2x, below its 2.0–2.5x target range. That balance-sheet flexibility supports continued capital investment, tuck-in M&A, dividend growth, and repurchases.
The company authorized a new $1 billion share-repurchase program and indicated an intention to repurchase roughly $200–300 million annually. For FY27, free cash flow is expected to decline to approximately $850 million from the exceptional $983 million generated in FY26, largely because working capital is expected to grow with volume, capital expenditures remain elevated, and certain incentive and legal-settlement payments are due.
The Q1 cash-flow result itself may be noisy, but commentary on working capital, the new Mentor, Ohio manufacturing investment, and buyback pacing will be relevant to the durability of the capital-return story.
STERIS closed at $232.89 on August 4, after recovering meaningfully from its June low but still below its January opening level. At that price, the stock trades at roughly 20.8x the midpoint of management’s FY27 adjusted-EPS guidance; that is a reasonable multiple for a durable, mid-single-digit organic grower, but it leaves limited room for a material deterioration in the growth or margin outlook.
That makes the report’s qualitative details important. A simple consensus beat without confirmation of AST normalization and margin progression may not be enough. Conversely, stable guidance plus confidence in the expected second-half AST acceleration could be sufficient to improve sentiment.
Bullish outcome - Total organic growth near the 6–7% full-year range despite AST’s difficult comparison. - Healthcare recurring revenue remains strong and capital-equipment demand/backlog stays stable. - AST softness is contained and management reaffirms the expected second-half improvement. - FY27 EPS and margin outlook are maintained, with tariffs, price, and inflation tracking to plan. - No adverse change in free-cash-flow expectations or capital-allocation priorities.
Bearish outcome - AST volumes weaken more sharply than expected or management lowers its segment outlook. - Healthcare orders, backlog, or capital-equipment demand show a meaningful slowdown. - Price does not offset tariffs, freight, labor, or input-cost pressure. - Margin expansion appears dependent on an aggressive second-half recovery. - Full-year EPS or free-cash-flow guidance is reduced.